Product
Follicle Stimulating Hormone Receptor T Cells
1 clinical trial
1 indication
Indication
Ovarian CancerClinical trial
A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2025-03-01